2024-01-22 23:09:28 ET
More on J&J and Bristol-Myers Squibb
- Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off?
- Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition
- Bristol-Myers Squibb: Big Dividend Yield, Unloved Big-Pharma Deal
- Bristol's Opdivo + Yervoy combo excels over long term in kidney cancer
- Bristol-Myers almost lost Karuna buyout to third party
Read the full article on Seeking Alpha
For further details see:
CAR-T therapies to get boxed warning on blood cancer risk